1-triacontanol derivatives

Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

536 41, C07H 1504

Patent

active

052833283

DESCRIPTION:

BRIEF SUMMARY
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a national phase of PCT/HU90/00082 filed Dec. 18, 1990 and based upon Hungarian National Application 6646/89 filed Dec. 18, 1989.


FIELD OF THE INVENTION

The present invention relates to novel 1-triacontanyl glycosides of formula I removing the hydrogen atom from the hydroxyl group being in the 1(alpha) or 1(beta) position, or the O-protected, preferably acetylated derivative thereof, carbon atom being in position 1 of the reaction product of glucose and mono-, di- or triethylene glycol or the O-protected, preferably O-acetylated derivative thereof.
The compounds of formula I of the invention are biologically active compounds and they are especially useful for the prevention and treatment of different diseases connected to aging.


BACKGROUND OF THE INVENTION

1-Triacontanol, the primary alcohol having 30 carbon atoms, was separated and identified by Chibnall in 1933.
According to U.S. Pat. No. 4,150,970, 1-triacontanol is a growth regulator for plants. This activity is also supported by Science, Vol. 195, pages 1339 to 1341.
According to published European patent application No. 78,533 a topical pharmaceutical composition comprising 1-triacontanol as active ingredient is useful for treating skin disorders.
No reference has been made so far to the different sugar derivatives of 1-triacontanol.
The use of 1-triacontanol and the examination of the mechanism of its activity is very difficult as this compound is highly lipophylic and hardly dissolves in water.


OBJECT OF THE INVENTION

It is an object of the invention to provide improved 1-triacontonyl compounds free from drawbacks of earlier 1-triacontonyl compounds.


DESCRIPTION OF THE INVENTION

We have found that the 1-tricontanol glycosides, according to the present invention dissolve well in water and have a less apolar character. The compounds have the formula I as defined above.


DETAILED DESCRIPTION OF THE INVENTION

In the description under the term "monosaccharide" the aldopentoses and aldohexoses are understood. When, in the formula I, m is 1, then the group derived from a monosaccharide by removing the hydrogen atom from the hydroxyl group being in the 1(alpha) or 1(beta) position may be a ribosyl, arabinosyl, xylosyl, lixosyl, allosyl, altrosyl, glucosyl, mannosyl, gulosyl, idosyl, galactosyl, talosyl group from which the glucosyl group is preferred.
The protected derivatives thereof may be such groups wherein one or more, preferably all of the free hydroxy groups are substituted by a conventional protecting group. The most preferred protecting group is the acetyl group. The most preferred protected monosaccharide residue represented by R when m=1 is glucosyl tetraacetate.
Under the term "oligosaccharides" the bioses, such as lactose, genciobiose, laminaribiose, maltose, cellobiose and the maltoligomers, such as maltotriose, maltotetraose, maltopentaose, maltohexaose, maltoheptaose, maltooctaose are understood. When m is 1, then the group derived from an oligosaccharide by removing the hydrogen atom from the hydroxyl group being in the 1(alpha) or 1(beta) position is preferably lactosyl, cellobiosyl, maltosyl, maltotriosyl, maltotetraosyl, matopentaosyl, maltohexaosyl, maltoheptaosyl or maltooctaosyl group.
The protected derivatives thereof may be such groups wherein one or more, and preferably all of the free hydroxy groups are substituted by a conventional protecting group. The most preferred protecting group is the acetyl group. The most preferred acetylated oligosaccharide residues represented by R when m=1 are cellobiosyl heptaacetate, lactosyl heptaacetate, maaltosyl heptaacetate, maltotriosyl decaacetate, maltotetraosyl tridecaacetate, maltohexaosyl nonadecaacetate, and maltoheptaosyl docosaacetate.
Thus a preferred group of compounds of formula I is that wherein the acetylated derivative thereof. A more preferred group of compounds of formula I is wherein group or the acetylated derivative thereof. The most preferred group of formula I is wherein maltotetraosyl, maltopentao

REFERENCES:
patent: 4713447 (1987-12-01), Letton
patent: 4847368 (1989-07-01), Lueders et al.
patent: 4990605 (1991-02-01), Lueders
patent: 4996306 (1991-02-01), McDaniel et al.
Packer, L., Toxicity, Antioxidants, and Metabolism, Molecular Basis of Membrane-Associated Diseases, pp. 335-343, Springer-Verlag, Berlin (1989).
D. Harman, "The Free Radial Theory of Aging", Clinical Aspects of Vitamin E, pp. 385-393 (Elsevier Science 1987).
Clinical Science and Molecular Medicine, 47, pp. 215-222 (1974).
Mechanisms of Aging and Development, 14, pp. 245-251 (Elsevier 1980).
Archives of Disease in Childhood, pp. 748-757, vol. 63 (1988).
Preventive Medicine, vol. 18, pp. 553-561 (1989).
Cancer Research, vol. 49, issued Aug. 1, 1989, Tietze et al, "Proton-Medicated Liberation of Aldophosphamide from a Nontoxic Prodrug: A Strategy for Tumor-seletive Activation of Cytocidal Drugs", pp. 4179-4184.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

1-triacontanol derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1-triacontanol derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-triacontanol derivatives will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-580626

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.